Positive results from the EMERALD-1 Phase 3 trial showed Imfinzi in combination with TACE and bevacizumab demonstrated a statistically significant improvement in the primary endpoint of progression-free survival.
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with…